{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nexus Surgical and Medicare Ltd
Nexus Surgical and Medicare Ltd Upgraded to Sell on Technical Improvements and Valuation Insights
Nexus Surgical and Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Feb 2026, driven primarily by a shift in technical indicators signalling a mild bullish trend. Despite this upgrade, the company continues to face valuation and fundamental challenges, with flat recent financial performance and a high price-to-book ratio. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced the rating change and what it means for investors.
Nexus Surgical and Medicare Ltd Downgraded to Strong Sell Amid Technical and Valuation Concerns
Nexus Surgical and Medicare Ltd, a player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating downgraded from Sell to Strong Sell as of 16 February 2026. This shift reflects a combination of deteriorating technical indicators, expensive valuation metrics, flat financial trends, and weakening overall quality assessments, signalling caution for investors amid a challenging market backdrop.
Are Nexus Surgical and Medicare Ltd latest results good or bad?
Nexus Surgical's latest results show a net profit increase and improved operating margins, but a significant revenue decline raises concerns about sustainability and stability, especially given its weak balance sheet and low promoter holding. Overall, the performance is mixed, indicating both operational improvements and underlying challenges.
Nexus Surgical and Medicare Ltd Upgraded to Sell on Technical Improvement Despite Flat Financials
Nexus Surgical and Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators signalling a mild bullish trend. Despite this positive technical momentum, the company continues to face challenges in valuation and financial performance, which temper the overall outlook for investors.
When is the next results date for Nexus Surgical and Medicare Ltd?
The next results date for Nexus Surgical and Medicare Ltd is 14 February 2026.
Nexus Surgical and Medicare Ltd is Rated Strong Sell
Nexus Surgical and Medicare Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 11 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 26 December 2025, providing investors with an up-to-date view of its performance and outlook.
Why is Nexus Surgical and Medicare Ltd falling/rising?
On 24-Dec, Nexus Surgical and Medicare Ltd experienced a sharp decline in its share price, falling 15.0% to close at a new 52-week low of ₹13.26. This significant drop comes after a period of volatility and marks a reversal following four consecutive days of gains.
Nexus Surgical and Medicare Stock Falls to 52-Week Low of Rs.13.26
Nexus Surgical and Medicare has reached a new 52-week low of Rs.13.26, marking a significant decline in its share price amid a volatile trading session. The stock's performance contrasts sharply with broader market trends, reflecting ongoing pressures within the Non Banking Financial Company (NBFC) sector.
Nexus Surgical Sees Revision in Market Evaluation Amidst Challenging Financial Trends
Nexus Surgical, a microcap player in the Non Banking Financial Company (NBFC) sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment comes amid a backdrop of subdued profit growth and valuation concerns, impacting investor sentiment and stock performance.
Nexus Surgical and Medicare Forms Death Cross Signalling Potential Bearish Trend
Nexus Surgical and Medicare, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory.
Nexus Surgical and Medicare Q2 FY26: Profitability Surge Masks Mounting Balance Sheet Concerns
Nexus Surgical and Medicare Ltd., a micro-cap medical essentials trading company, reported net profit of ₹0.17 crores for Q2 FY26, marking a sequential increase of 13.33% from Q1 FY26's ₹0.15 crores, though this represented a decline of 19.05% compared to ₹0.21 crores in Q2 FY25. The company, with a modest market capitalisation of ₹9.00 crores, has demonstrated improved profitability margins despite revenue volatility, yet its stock continues to languish, trading at ₹16.51 as of November 19, 2025—down 40.35% year-to-date and hovering near its 52-week low of ₹13.80.
Why is Nexus Surgical falling/rising?
As of 18-Nov, Nexus Surgical and Medicare Ltd's stock price is declining at 16.80, down 2.04%, and has underperformed its sector. The stock is trading below all major moving averages, indicating a bearish trend, with a significant drop in investor participation and a concerning year-to-date decline of 39.31%.
How has been the historical performance of Nexus Surgical?
Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profit after tax rising from 0.17 Cr to 0.50 Cr, while maintaining zero debt. The company's operating profit margin improved, reflecting a positive financial trajectory overall.
How has been the historical performance of Nexus Surgical?
Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profit after tax rising from 0.17 Cr to 0.50 Cr during the same period, while maintaining a zero debt position. The company's earnings per share improved from -9.69 in March 2020 to 0.91 in March 2025.
Why is Nexus Surgical falling/rising?
As of 14-Nov, Nexus Surgical and Medicare Ltd's stock price has increased to Rs 17.98, up 8.97%, and is trading above all key moving averages, indicating a positive trend. Despite recent gains, the stock has underperformed the Sensex year-to-date, down 35.04%.
How has been the historical performance of Nexus Surgical?
Nexus Surgical has shown significant financial growth, with net sales rising to 5.72 Cr in Mar'25 from 3.47 Cr in Mar'24, resulting in an operating profit of 0.67 Cr and a profit after tax of 0.50 Cr. The company's earnings per share improved to 0.91, reflecting enhanced shareholder value and a solid growth trajectory.
Nexus Surgical Faces Evaluation Adjustment Amid Flat Financial Performance and Stock Underperformance
Nexus Surgical and Medicare, a microcap in the NBFC sector, has experienced a recent score adjustment amid flat financial performance for the quarter ending June 2025. Despite a year-over-year profit increase, the stock has underperformed against the BSE500 index, raising concerns about its long-term fundamentals.
When is the next results date for Nexus Surgical?
The next results date for Nexus Surgical is 14 November 2025.
Why is Nexus Surgical falling/rising?
As of 11-Nov, Nexus Surgical and Medicare Ltd's stock price is Rs 16.21, down 9.89% and underperforming significantly compared to the market, with a year-to-date decline of 41.44%. Despite increased delivery volume, the stock remains in a bearish trend, trading below all key moving averages.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
